<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545882</url>
  </required_header>
  <id_info>
    <org_study_id>10-059</org_study_id>
    <secondary_id>OTT10-06</secondary_id>
    <nct_id>NCT01545882</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer</brief_title>
  <acronym>OTT10-06</acronym>
  <official_title>A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being offered to patients who have hormone resistant prostate cancer (HRPC).&#xD;
      This means that their prostate cancer is no longer responding to standard hormonal therapy.&#xD;
&#xD;
      The purpose of this study is to determine whether Degarelix will be able to stop the PSA from&#xD;
      rising in patients with hormone resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study of a GnRH antagonist drug, Degarelix, for use in hormone resistant&#xD;
      prostate cancer patients who have had biochemical PSA progression despite the use of total&#xD;
      androgen blockade therapy. Patients will receive at least six monthly injections of Degarelix&#xD;
      unless the patient shows radiographic or symptomatic disease progression, intolerable&#xD;
      toxicity or decides to withdraw from the study. Patients will be evaluated for measures of&#xD;
      efficacy, toxicity and disease progression during treatment and afterwards until&#xD;
      radiologically confirmed metastatic disease progression or until the patient is removed from&#xD;
      the study.&#xD;
&#xD;
      Overall objective:&#xD;
&#xD;
      The efficacy of Degarelix as a treatment for HRPC will be evaluated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Negative study; Principal Investigator chose to prematurely terminate the study.&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Progression</measure>
    <time_frame>Monthly for 6 months then every 3 months</time_frame>
    <description>Blood work will be done once a month during the 6 months of treatment then every 3 months until disease progression or participant withdrawal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease progression</measure>
    <time_frame>Monthly for 6 months then every 3 months</time_frame>
    <description>Blood work will be done once a month during the 6 months of treatment then every 3 months until disease progression or participant withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy of Testosterone, LH and FSH suppression with Degarelix</measure>
    <time_frame>Monthly for 6 months then every 3 months</time_frame>
    <description>Blood work will be done once a month during the 6 months of treatment then every 3 months until disease progression or participant withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of monthly injections of Degarelix on Health Related Quality of Life Issues in patients with prostate cancer</measure>
    <time_frame>Month 3 and 6 then every 3 months</time_frame>
    <description>The EPIC-26 Expanded Prostate Cancer Index Composite is used to measure quality of life issues in patients with prostate cancer. The questionnaire will be done months 3 and 6 then every 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.</description>
    <arm_group_label>Degarelix</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior trial of total androgen blockade&#xD;
&#xD;
          -  Confirmed biochemical PSA progression on agonist therapy, defined as ≥ 50% increase in&#xD;
             PSA between 2 measurements, taken at least 1 week apart. In patients that are&#xD;
             currently on total androgen blockade (LHRH agonist plus non-steroidal anti-androgen)&#xD;
             there must be a trial withdrawal of androgen receptor antagonists to ensure that there&#xD;
             is no PSA response (6 weeks for bicalutamide and 4 weeks for flutamide or nilutamide).&#xD;
&#xD;
          -  Radiologically confirmed non-metastatic disease within 90 days of registration based&#xD;
             on negative chest radiographs, CT Scan Abdomen/Pelvis and Bone scan&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Serum testosterone of ≤ 50 mg/dl&#xD;
&#xD;
          -  PSA ≥ 2.0 ng/ml&#xD;
&#xD;
          -  White blood cell count ≥ 3000/mm3&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limits of normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper limits of normal&#xD;
&#xD;
          -  Alanine transaminase ≤ 1.25 x upper limits of normal&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 months&#xD;
&#xD;
          -  Able and willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, PC-SPES,&#xD;
             ketoconazole or other second line hormonal therapy (other than non-steroidal&#xD;
             anti-androgens or Androcur)&#xD;
&#xD;
          -  Known allergy to GnRH agonists or antagonists&#xD;
&#xD;
          -  Previous treatment with Degarelix&#xD;
&#xD;
          -  Major surgery within 4 weeks of registration&#xD;
&#xD;
          -  Grade ≥ 3 peripheral neuropathy&#xD;
&#xD;
          -  Severe, active co-morbidity such as unstable angina, congestive heart failure or&#xD;
             myocardial infarction within the last 6 months or congenital long QT syndrome&#xD;
&#xD;
          -  Acute deep vein thrombosis or pulmonary embolism&#xD;
&#xD;
          -  Taking anti-arrhythmia medication&#xD;
&#xD;
          -  Second malignancy other than non-melanoma skin cancer unless disease free ≥ 5 years.&#xD;
&#xD;
          -  Prior orchiectomy for prostate cancer&#xD;
&#xD;
          -  PSA &gt; 100 ng/mL&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Malone, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margeret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>hormone-resistant</keyword>
  <keyword>degarelix</keyword>
  <keyword>firmagon</keyword>
  <keyword>anti-androgens</keyword>
  <keyword>total androgen blockade</keyword>
  <keyword>injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

